Clinical trials: Alzheimer Disease
Alzheimer's Disease
An Observational Study of LEQEMBI in Routine Clinical Practice in Taiwan
The primary purpose of this study is to describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities (ARIA)-oedema/effusion (ARIA-E), ARIA-microhemorrhage and haemosiderin deposit…
- Trial name
- NCT07869264
- Testing
- No Intervention
- Where
- 12 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- Eisai Taiwan Inc.
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 1 (NCT06976216)
- Testing
- KarXT, KarX-EC
- Where
- 119 sites in United States, Argentina and 17 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
This is a research study to evaluate the safety of an investigational autologous cell product obtained from participant's own adipose tissue as a possible treatment for Alzheimer disease.
- Trial name
- NCT05667649
- Testing
- RB-ADSC
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Regeneration Biomedical, Inc.
Healthy
A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants
The purpose of this study is to assess the effects of strong cytochrome P450 (CYP) 3A4 inhibitors (Itraconazole and Clarithromycin), on pharmacokinetics (PK) (study of the way a drug enters and leaves the blood and tissues over…
- Trial name
- NCT02197884
- Testing
- JNJ-54861911, 25 mg, Itraconazole 200 mg, Clarithromycin 500 mg
- Where
- Belgium
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Alzheimer Disease
BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
The study is designed to compare the effects of BI 409306 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease
- Trial name
- NCT02337907
- Testing
- BI 409306, Donepezil
- Where
- 60 sites in United States, Austria and 9 more
- Volunteers
- 329 people
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease, Healthy Volunteers
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
This study is being done for the following reasons: To determine the safety of LY2886721 and any side effects that may be associated with it and to see how much of the study drug is in the blood and the cerebrospinal fluid (CSF)…
- Trial name
- NCT01807026
- Testing
- LY2886721
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Observational Study Of Donepezil In Routine Clinical Practice
To characterize the comorbidities and medications of patients treated with donepezil in a routine clinical practice and to verify the therapeutic response of these patients.
- Trial name
- NCT00843115
- Testing
- donepezil
- Volunteers
- 370 people
- Sponsor
- Pfizer
Alzheimer's Disease
Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients
The purpose of this Phase IIa study is to determine whether the AD Immunotherapeutic Vaccine (UB-311), targeting the amyloid beta peptide (N-terminal amino acids, 1-14), is safe and immunogenic in mild AD patients.
- Trial name
- NCT02551809
- Testing
- UB-311
- Where
- 4 sites in Taiwan
- Volunteers
- 43 people
- Sponsor
- United Neuroscience Ltd.
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD)
Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention
The study will explore the impact of photobiomodulation (PBM), pulsating at frequencies of red (660nm) and near-infrared (810nm)(NIR), concurrent with a ketogenic dietary protocol (serum ketones @ .5 - 2.0 mmol/L) to mediate…
- Conditions
- Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
- Trial name
- NCT03859245
- Testing
- Photobiomodulation, Ketogenic diet
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.
Alzheimer's Disease, Traumatic Brain Injury
Clinical Evaluation of Flortaucipir F 18
This study is designed to expand the database of flortaucipir F 18 safety and tau binding as measured by PET imaging and to provide standardized conditions for flortaucipir PET use, data collection and analysis to facilitate…
- Conditions
- Alzheimer's Disease, Traumatic Brain Injury, Depression
- Trial name
- NCT02278367
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- 5 sites in United States
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Psychosis Associated With Alzheimer's Disease
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease.
- Trial name
- NCT05511363
- Testing
- KarXT
- Where
- 129 sites in United States, Bulgaria and 11 more
- Volunteers
- 410 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Alzheimer Disease, Early Onset
A Study to Assess THN391 in Subjects With Alzheimer's Disease
This is a Phase 1b study to evaluate different doses of the drug and see whether a drug is safe and how it behaves in the body. THN391 has already been assessed in healthy people without Alzheimer's disease.
- Trial name
- NCT06814730
- Testing
- THN391
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 19 people
- Sponsor
- Therini Bio, Inc.
Alzheimer's Disease
A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI
To purpose of this study is to estimate the effect of donepezil on Neuropsychological Testing (NPT) and brain Proton Magnetic Resonance Spectroscopy.
- Trial name
- NCT00483028
- Testing
- donezepil (Aricept)
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer's Disease
A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants
This is a first in human Phase 1 study to evaluate the safety, tolerability and pharmacokinetics with healthy young and elderly adult male volunteers after receiving single and multiple ascending dose of BEY2153.
- Trial name
- NCT04476303
- Testing
- BEY2153
- Where
- South Korea
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- BeyondBio Inc.
Alzheimers Disease
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).
- Trial name
- TRONTIER 2 (NCT07170150)
- Testing
- Trontinemab
- Where
- 147 sites in United States, Argentina and 14 more
- Volunteers
- 1,060 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
Evaluation of the COGNISION(TM) System as an Event-related Potential (ERP) Collection System.
This study will evaluate a handheld event-related potential (ERP) testing device from Neuronetrix, Inc. as a method to collect ERP data in an outpatient setting.
- Trial name
- NCT00582127
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Neuronetrix, Inc.
Alzheimer's Disease
Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers
This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed either AVA102670 or AVA102672.
- Trial name
- NCT00490568
- Testing
- Rosiglitazone XR
- Where
- 272 sites in United States, Argentina and 27 more
- Volunteers
- 1,461 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
AAB-001 in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT00112073
- Testing
- bapineuzumab
- Where
- 26 sites in United States
- Volunteers
- 234 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer's Disease
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
The purpose of this study is to evaluate the long-term safety and tolerability of Dimebon in patients with Alzheimer's disease.
- Trial name
- NCT00939783
- Testing
- Dimebon
- Where
- 105 sites in United States, Canada and 1 more
- Volunteers
- 649 people
- Sponsor
- Pfizer
Alzheimer Disease
Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease
The primary purpose of this study is to assess biomarker known as amyloid beta peptide 40 (Ab40) in Cerebrospinal Fluid (CSF), following a single oral dose of PAZ-417 in subjects with Alzheimer Disease (AD).
- Trial name
- NCT00739037
- Testing
- PAZ-417
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer